U.S. markets closed
  • S&P 500

    4,594.62
    -106.84 (-2.27%)
     
  • Dow 30

    34,899.34
    -905.04 (-2.53%)
     
  • Nasdaq

    15,491.66
    -353.57 (-2.23%)
     
  • Russell 2000

    2,245.94
    -85.52 (-3.67%)
     
  • Crude Oil

    68.15
    -10.24 (-13.06%)
     
  • Gold

    1,788.10
    +1.20 (+0.07%)
     
  • Silver

    23.14
    -0.40 (-1.70%)
     
  • EUR/USD

    1.1322
    +0.0110 (+0.99%)
     
  • 10-Yr Bond

    1.4820
    -0.1630 (-9.91%)
     
  • GBP/USD

    1.3342
    +0.0022 (+0.16%)
     
  • USD/JPY

    113.2600
    -2.0790 (-1.80%)
     
  • BTC-USD

    54,511.42
    +172.31 (+0.32%)
     
  • CMC Crypto 200

    1,365.60
    -89.82 (-6.17%)
     
  • FTSE 100

    7,044.03
    -266.34 (-3.64%)
     
  • Nikkei 225

    28,751.62
    -747.66 (-2.53%)
     

SHAREHOLDER ALERT: Morris Kandinov Investigating ODT, AYTU, EAR, and CORT; Shareholders are Encouraged to Contact the Firm

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Odonate Therapeutics, Inc., Aytu Biopharma, Inc., Eargo, Inc., and Corcept Therapeutics, Inc. If you are a current owner of shares of any of these stocks, contact leo@moka.law or call (619) 708-3993.

Odonate Therapeutics, Inc. (NASDAQ: ODT) Accused of Misleading Investors

On August 4, 2021, Judge Marilyn Huff. of the United States District Court for the Southern District of California issued an order denying the defendants’ motion to dismiss in the pending securities class action against Odonate Therapeutics, Inc., paving the way for litigation to proceed. Odonate is a pharmaceutical company formerly focused on the development of therapeutics for the treatment of cancer. According to the complaint, defendants made false and misleading statements regarding the company’s sole drug candidate, tesetaxel. On August 24, 2020, the company disclosed disappointing results from the trial of tesetaxel. On March 22, 2021, the company disclosed that it was ending development of tesetaxel following feedback from the U.S. Food and Drug Administration that the drug was unlikely to receive approval on the basis of its clinical data package, and that it would be winding down operations. Morris Kandinov is investigating Odonate regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders. To learn more about this investigation and your rights, visit: https://moka.law/case-contact-form/. Representation is contingency based, no out of pocket costs.

Aytu Biopharma, Inc. (NASDAQ: AYTU) Shareholder Rights Investigation

Morris Kandinov is investigating Aytu Biopharma, Inc. regarding corporate governance failures, possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders, related to recent transactions and/or events at the company. To learn more about this investigation and your rights, visit: https://moka.law/case-contact-form/. Representation is contingency based, no out of pocket costs.

Eargo, Inc. (NASDAQ: EAR) Shareholder Rights Investigation

Morris Kandinov is investigating Eargo, Inc. regarding corporate governance failures, possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders, related to recent transactions and/or events at the company. To learn more about this investigation and your rights, visit: https://moka.law/case-contact-form/. Representation is contingency based, no out of pocket costs.

Corcept Therapeutics, Inc. (NASDAQ: CORT) Accused of Misleading Investors

On August 24, 2021, Judge Lucy Koh of the United States District Court for the Northern District of California issued an order denying in part the defendants’ motion to dismiss in the pending securities class action against Corcept Therapeutics, Inc., paving the way for litigation to proceed. Corcept is a pharmaceutical company that develops medications to treat severe metabolic, oncologic, and psychiatric disorders. Corcept’s drug Korylm is a cortisol receptor blocker used to control hyperglycemia. According to allegations, Corcept was involved in an off-label marketing scheme involving Korlym. Morris Kandinov is investigating Corcept regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders. To learn more about this investigation and your rights, visit: https://moka.law/case-contact-form/. Representation is contingency based, no out of pocket costs.

Concerned shareholders are encouraged to contact Leo Kandinov to learn more:

leo@moka.law
(619) 708-3993
moka.law

Morris Kandinov LLP is a national law firm that specializes in recovering investment losses and protecting stockholder rights. We work on contingency (i.e., you do not pay our fees out-of-pocket), and our attorneys have made substantial recoveries for investors in jurisdictions across the country. The firm would be happy to further discuss these matters, and any legal rights or remedies potentially available to you, at no charge.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contact:

Leo Kandinov, Partner
leo@moka.law
619-708-3993
550 West B Street, 4th Floor
San Diego, CA 92101
moka.law